News
Press Releases
2016/01/08
WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group
SHANGHAI, January 8, 2016 -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, today congratulated Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Read more2015/12/10
WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the completion of its merger (the "Merger") with WuXi Merger Limited("Merger Sub"), a wholly-owned subsidiary of New WuXi Life Science Limited ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2015 and amended on October 20, 2015 and November 20, 2015, among the Company, Parent and Merger Sub. As a result of the Merger, Parent has acquired the Company (which is now a direct wholly owned subsidiary of Parent) in a cash transaction valued at approximately US$3.3 billion.
Read more2015/12/08
WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China
SHANGHAI and RALEIGH N.C., December 8, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and PRA Health Sciences, Inc. (NASDAQ: PRAH), a leading global clinical contract research organization, today announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong. The two companies formed a joint venture for this purpose in March 2013.
Read more2015/12/07
Dr. Ge Li Receives Executive of the Year Award from SCRIP
SHANGHAI, Dec. 7, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that Dr. Ge Li, WuXi's Chairman and CEO, was named Executive of the Year at the 11th annual SCRIP Awards on December 2 in London. Established by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech industry, the annual SCRIP Awards recognize the industry's highest achievements by both companies and individuals across the value chain.
Read more2015/11/11
WuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China
SHANGHAI, November 11, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and Eli Lilly and Company (NYSE: LLY) today announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
Read more